Justin Klee | BiotechTV

top of page

Search

The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset

The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset

Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an...

Jul 12, 2024

Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy

Amylyx's Co-CEOs comment on Friday's European CHMP decision on their ALS therapy

Josh Cohen and Justin Klee on the negative opinion, what it means for ALS patients in Europe, and a new statistical analysis of CENTAUR.

Oct 16, 2023

Catching up with the co-founders of Amylyx on the launch of their ALS treatment

Catching up with the co-founders of Amylyx on the launch of their ALS treatment

Josh Cohen and Justin Klee discuss the launch of RELYVRIO, the PHOENIX P3 trial, and reflect on the roller coaster of the last year.

Aug 15, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page